Transcript of Earnings Call - Q1 FY27

Emcure Ref: EPL/CS/SE/0073/2026 Date: August 12, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai - 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Transcript of Earnings Call – Q1 FY27 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated July 15, 2026, please find enclosed the transcript of the Earnings Call for Q1 FY27, held on Thursday, August 06, 2026 at 4:00 p.m. (IST). The above-mentioned transcript is also being uploaded on the website of the Company i.e. www.emcure.com. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Pharmaceuticals Limited Q1 FY27 Earnings Conference Call August 06, 2026 MANAGEMENT PARTICIPANTS: Mr. Satish Mehta – Managing Director & CEO Mr. Tajuddin Shaikh – Chief Financial Officer Mr. Samit Mehta – Whole-Time Director and COO Mr. Vikas Thapar – President, Corporate Development, Strategy & Finance Mr. Piyush Nahar – Executive Vice President, Corporate Development & Strategy Mr. Saurabh Paliwal – Head, Investor Relations Prepared Remarks Session Moderator: Ladies and gentlemen, good day, and welcome to the Emcure Pharmaceuticals Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Please note that this conference is being recorded. I now hand the conference over to Mr. Saurabh Paliwal, Head of Investor Relations. Thank you, and over to you, sir. Saurabh Paliwal: Thank you, Dorwin. Good afternoon, everyone, and welcome to Q1 FY27 Earnings Conference Call of Emcure Pharmaceuticals. We will begin today's session with opening remarks from the management, followed by a Q&A session. Joining me today on this call are Mr. Satish Mehta, Managing Director and CEO; Mr. Taj Shaikh, Chief Financial Officer; Mr. Samit Mehta, Whole-Time Director and COO; Mr. Vik Thapar, President, Corporate Development, Strategy and Finance; and Mr. Piyush Nahar, Executive Vice President, Corporate Development and Strategy. We hope you had an opportunity to review the financial results, the results presentation and the press release, which was released earlier this afternoon. Before we start, please note that this call is being recorded. I also need to remind everyone about the safe harbor related to today's call. Certain statements made during this call may be forward-looking in nature. These statements are based on our current expectations, assumptions and management's views as of today. Actual results may differ materially due to a range of factors, including market conditions, regulatory developments, competitive dynamics, operational factors and other risks and uncertainties. The detailed disclaimer accompanying the results presentation and the press release applies to this earnings call. I will now hand over the call to Mr. Mehta to begin his opening remarks. Over to you, sir. Satish Mehta: Thank you, Saurabh. Good afternoon to all of you. This is Satish Mehta, CEO of Emcure, and I'm absolutely pleased to speak to you post publication of our Q1 results, which I believe you must have seen it by this time. Before I start talking about the performance for the quarter, which has ended, I would like to share some important Board and organizational updates. Number one, our Chairman, Mr. Berjis Desai, has been appointed as member of National Commission for Minorities. It's a full-time employment of Government of India. Page 2 of 16 As a result of this appointment, Berjis Desai is going to step down from the Boards of all listed companies. So obviously, he will retire from the Board of Directors of Emcure at the conclusion of our Annual General Meeting. Berjis and I have been working together for more than 35 years, and he has been very much responsible in shaping the value system and culture of the organization and provided immense guidance and contribution to Emcure. Obviously, being a stalwart and a very eminent lawyer in his own right, he has helped in improving the governance standards and institutional processes of the company. We will obviously continue what we have jointly built over a period of last 35 years and take it to the next level. The entire management of Emcure and every Emcurean is grateful to Berjis for the contribution that he has given to company in the last 35 years, and things wouldn't have happened but for his active participation. With the recommendation of the Board, I will now take on the role of Chairman in addition to my existing role as Managing Director and CEO of the Company post the conclusion of the upcoming Annual General Meeting I assure all of you that company strategy, operations, execution, everything remains unchanged. In terms of this new position that has been entrusted to me, I feel humbled and I'm committed to give more than what I have done so far, and I will work very closely with the Board, senior management team and each and every Emcurean to take the company to the next level. The second important announcement I would like to make is that Samit Mehta now takes over as Chief Operating Officer of Emcure. As far as Samit is concerned, he is extremely passionate about science and technology. He has done his MBA from Wharton and has spent more than two decades with the organization. He has also been involved in giving a lot of innovative products and has worked very closely with the R&D and manufacturing. Going forward, he will have a broader oversight of group R&D, manufacturing operations, and licensing activities. Samit will also play a bigger role, not only in the areas where he is directly involved, but also in overall strategy. He will get more involved in the management of the company and clear signal to everyone about the way forward. The third important thing that has happened is we have just recently acquired 12.05% minority stake in Gennova, making it a 100% owned subsidiary of Emcure. The strategic control of our biological platform will ensure that we have a sharpened focus on biosimilars and adjacent therapeutic platforms. We began the journey 15, 16 years back. As far as Samit is concerned, because of his passion for science and technology, apart from being Chief Operating Officer of Emcure, he also serves Chief Executive Officer of Gennova, our biotech arm wholly owned 100% subsidiary. Page 3 of 16 He will obviously be focusing on taking Gennova, biosimilars and other technologies to the next level because I personally believe that, given the development at the global level, a lot is happening in the field of biologics. Under Samit's leadership, Gennova will have a robust product pipeline, particularly as biosimilars and biologics are going to play a very important role. The Gennova consolidation now gives us full control across all our Indian and foreign subsidiaries. With Gennova, Zuventus and all our other subsidiaries now 100% owned by the parent company, we have a very simplified and aligned group structure that ensures strategic coordination across all businesses. Having discussed about these three major events, let me focus on our quarterly performance, which I believe most of you have seen. Q1 FY27 marks the beginning of the second year of our 5-year plan, and I'm very pleased to say that we have started on a [Showing first 8,000 characters — download PDF for full document]